Arrowhead Pharmaceuticals Unveils Data From Two Studies
November 09 2018 - 1:15PM
Dow Jones News
By Michael Dabaie
Arrowhead Pharmaceuticals Inc. (ARWR) Friday unveiled data from
a pair of studies to be presented at the annual meeting of the
American Association for the Study of Liver Disease.
The company is presenting data from a Phase 1 study of ARO-AAT,
its RNA interference therapeutic to treat a rare genetic liver
disease associated with alpha-1 antitrypsin deficiency.
"ARO-AAT at single- and multiple-doses produced robust and
consistent reductions in serum AAT levels," the company said.
Reductions were sustained for greater than 14 weeks indicating that
quarterly or less frequent dosing appears feasible.
The company also unveiled preliminary clinical data from a Phase
1/2 study of ARO-HBV, a therapeutic candidate being developed as a
potential treatment for patients with chronic hepatitis B virus
infection.
ARO-HBV administered subcutaneously appears to be well-tolerated
at single or multiple monthly doses up to 400 mg. Strong hepatitis
B surface antigen responses were observed in all hepatitis B virus
patients, the company said.
Arrowhead recently entered into a license agreement with Janssen
Pharmaceuticals Inc., part of Johnson & Johnson (JNJ), to
develop and commercialize ARO-HBV.
Arrowhead shares were recently down 5%, to $14.57.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 09, 2018 13:00 ET (18:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Sep 2023 to Sep 2024